Are Investors Undervaluing Pfizer (PFE) Right Now?

28.11.24 15:40 Uhr

Werte in diesem Artikel
Aktien

24,75 EUR 0,31 EUR 1,27%

Indizes

PKT PKT

17.376,2 PKT -3,2 PKT -0,02%

2.883,2 PKT -11,8 PKT -0,41%

5.998,7 PKT -22,9 PKT -0,38%

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.One company value investors might notice is Pfizer (PFE). PFE is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A. The stock holds a P/E ratio of 8.82, while its industry has an average P/E of 16.87. Over the past year, PFE's Forward P/E has been as high as 19.41 and as low as 8.50, with a median of 11.02.We also note that PFE holds a PEG ratio of 0.83. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. PFE's industry has an average PEG of 1.34 right now. Within the past year, PFE's PEG has been as high as 2.77 and as low as 0.80, with a median of 1.08.Value investors also love the P/S ratio, which is calculated by simply dividing a stock's price with the company's sales. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. PFE has a P/S ratio of 2.44. This compares to its industry's average P/S of 4.16.Finally, investors will want to recognize that PFE has a P/CF ratio of 13.19. This metric focuses on a firm's operating cash flow and is often used to find stocks that are undervalued based on the strength of their cash outlook. PFE's P/CF compares to its industry's average P/CF of 26.47. Within the past 12 months, PFE's P/CF has been as high as 43.59 and as low as 8.88, with a median of 19.97.These figures are just a handful of the metrics value investors tend to look at, but they help show that Pfizer is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, PFE feels like a great value stock at the moment.Free: 5 Stocks to Buy As Infrastructure Spending SoarsTrillions of dollars in Federal funds have been earmarked to repair and upgrade America’s infrastructure. In addition to roads and bridges, this flood of cash will pour into AI data centers, renewable energy sources and more.In, you’ll discover 5 surprising stocks positioned to profit the most from the spending spree that’s just getting started in this space.Download How to Profit from the Trillion-Dollar Infrastructure Boom absolutely free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Pfizer

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Pfizer

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Pfizer Inc.

Analysen zu Pfizer Inc.

DatumRatingAnalyst
14.11.2024Pfizer NeutralUBS AG
01.11.2024Pfizer NeutralUBS AG
30.10.2024Pfizer BuyGoldman Sachs Group Inc.
29.10.2024Pfizer BuyJefferies & Company Inc.
25.10.2024Pfizer NeutralJP Morgan Chase & Co.
DatumRatingAnalyst
30.10.2024Pfizer BuyGoldman Sachs Group Inc.
29.10.2024Pfizer BuyJefferies & Company Inc.
27.09.2024Pfizer BuyJefferies & Company Inc.
17.09.2024Pfizer BuyJefferies & Company Inc.
31.07.2024Pfizer KaufenDZ BANK
DatumRatingAnalyst
14.11.2024Pfizer NeutralUBS AG
01.11.2024Pfizer NeutralUBS AG
25.10.2024Pfizer NeutralJP Morgan Chase & Co.
07.10.2024Pfizer NeutralJP Morgan Chase & Co.
23.08.2024Pfizer HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
DatumRatingAnalyst
03.05.2018Pfizer VerkaufenDZ BANK
16.05.2017Pfizer SellCitigroup Corp.
27.11.2012Pfizer verkaufenHamburger Sparkasse AG (Haspa)
28.08.2012Pfizer verkaufenHamburger Sparkasse AG (Haspa)
10.01.2012Pfizer verkaufenHamburger Sparkasse AG (Haspa)

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Pfizer Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"